UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 29, 2016
CIDARA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-36912 | 46-1537286 | ||
(State of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: (858) 752-6170
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.02 | Termination of a Material Definitive Agreement. |
On August 29, 2016, Dirk Thye, M.D., resigned from his position as Chief Medical Officer of Cidara Therapeutics, Inc. (Cidara), effective as of September 2, 2016. Accordingly, the Employment Letter Agreement by and between Cidara and Dr. Thye dated July 15, 2014 will terminate as of September 2, 2016.
The disclosure set forth under Item 5.02 of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
(b) On August 29, 2016, Dr. Thye resigned from his position as Chief Medical Officer of Cidara, effective as of September 2, 2016.
Dr. Thye has accepted a position as Chief Executive Officer of Agenovir Corporation, a company using computationally engineered nuclease technology for research and development programs.
Cidara has named Taylor Sandison, M.D., M.P.H., to the position of Vice President, Clinical Development and Acting Chief Medical Officer, effective as of September 2, 2016. Dr. Sandison has been with Cidara since October 2015. Prior to joining Cidara, Dr. Sandison was Senior Medical Director at Merck from February 2015 to October 2015 after Mercks acquisition of Cubist Pharmaceuticals, Inc. Dr. Sandison was Senior Medical Director at Cubist from July 2014 to January 2015 after Cubists acquisition of Trius Therapeutics, Inc. Dr. Sandison joined Trius in April 2013 as Director of Clinical Science. Prior to Trius, Dr. Sandison held positions of increasing responsibility, including Director, Medical Affairs, at Novartis Diagnostics from 2010-2013, while simultaneously being a member of the Clinical Adjunct Faculty in the Department of Medicine at Stanford University. Prior to that, he was a faculty member in the Division of Infectious Diseases at the University of Washington School of Medicine. Dr. Sandison received B.S. and B.A. degrees from Dartmouth College, and M.D. and M.P.H. degrees from the University of Washington. He completed his residency training at the University of Colorado and his fellowship training at the University of Washington. Dr. Sandison holds Board Certifications in Infectious Diseases and Internal Medicine.
In connection with Dr. Thyes resignation, Cidara and Dr. Thye entered into a Consulting and Independent Contractor Agreement effective as of September 2, 2016 (the Consulting Agreement) under which Dr. Thye will provide medical, clinical and/or regulatory advisory services at the direction of Cidara. The sole consideration for the provision by Dr. Thye of such services will be the continued vesting of Dr. Thyes unvested restricted stock and other equity awards under Cidaras equity incentive plans during the term of the Consulting Agreement. The initial term of the Consulting Agreement is through December 31, 2016, but the Consulting Agreement will automatically be renewed for successive six-month terms unless either party notifies the other party of its intention to terminate the Consulting Agreement in writing at least 30 days in advance of the expiration of the then-current term. In addition, either party may terminate the Consulting Agreement upon 30 days prior written notice to the other party.
The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the full text of such Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits.
Exhibit No. |
Description | |
10.1 | Consulting and Independent Contractor Agreement between Cidara Therapeutics, Inc. and Dirk Thye, M.D., effective as of September 2, 2016. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 1, 2016 | CIDARA THERAPEUTICS, INC. | |||||
By: | /s/ Jeffrey L. Stein, Ph.D. | |||||
Name: | Jeffrey L. Stein, Ph.D. | |||||
Title: | President and Chief Executive Officer |
3
EXHIBIT INDEX
Exhibit No. |
Description | |
10.1 | Consulting and Independent Contractor Agreement between Cidara Therapeutics, Inc. and Dirk Thye, M.D., effective as of September 2, 2016. |
4
Exhibit 10.1
CONSULTING AND INDEPENDENT CONTRACTOR AGREEMENT
THIS AGREEMENT (Agreement) is made and entered into as of the 2nd of September, 2016 (the Effective Date), by and between CIDARA THERAPEUTICS, INC., a Delaware corporation (the Company), and Dirk Thye, M.D. (Consultant). The Company desires to retain Consultant as an independent contractor to perform Services (defined below) for the Company and Consultant is willing to perform such Services, on terms set forth more fully below. In consideration of the mutual promises contained herein, the parties agree as follows:
1. Engagement of Services. Consultant agrees to consult with the Company and to perform medical, clinical and/or regulatory advisory services at the direction of the Company (the Services). Consultant will perform Services for at most four (4) hours per week, on average, during the Term of this Agreement. The Services may be performed ad-hoc, on a regular or irregular basis, at times, at places and in a manner mutually acceptable to Consultant and Company. It is the Companys intention that such work be covered by the attorney-client privilege to the maximum extent permitted by law, and Consultant agrees to cooperate with the Company in all reasonable respects in such matters.
2. Compensation. As the sole consideration for Consultant performing Services hereunder, the Company will allow for continued vesting of all of Consultants equity awards, including but not limited to unvested restricted stock, under the Companys equity incentive plans during the Term of this Agreement.
3. Independent Contractor. It is understood and agreed that Consultant is an independent contractor and not an employee of the Company. Consultant has no authority to obligate the Company by contract or otherwise. Consultant will not be eligible for any Company employee benefits, nor will the Company make deductions from any amounts payable to Consultant for taxes. Taxes shall be the sole responsibility of Consultant.
4. Nonsolicitation/Nondisparagement.
(a) During the term of this Agreement and for one (1) year after its termination, Consultant will not personally or through others offer to hire, solicit for employment, attempt to solicit or induce any officer, employee or agent of the Company to terminate his or her employment or contractual relationship with the Company. The foregoing shall not limit Consultants ability to hire anyone (as an employee, consultant or otherwise) that responds to a general solicitation published by Consultant or any employer of Consultant.
(b) Consultant will not at any time directly (or through any other person or entity) make any statements (whether orally or in writing) which are intended to be derogatory or damaging to the Company or any of its subsidiaries, their respective businesses, activities, operations, affairs, reputations or prospects or any of their respective officers, employees, directors, partners, agents or shareholders; provided that Consultant may comment generally on industry matters in response to inquiries from the press and in other public speaking engagements.
5. Companys Proprietary Information, Nondisclosure and Inventions. Consultant recognizes that Consultant will be exposed to, have access to and be engaged in the development of information (including all tangible and intangible manifestations) regarding the patents, copyrights, trademarks, trade secrets, technology, strategic sales/marketing plans, and business of the Company and agrees as follows:
(a) All Proprietary Information (as defined below), whether presently existing or developed in the future, shall be the sole property of the Company and its assigns. In addition, the Company
Confidential Information
and its assigns shall be the sole owner of all intellectual property and other rights in connection with such Proprietary Information. During the term of this Agreement and after its termination, Consultant will keep in confidence and trust all Proprietary Information and shall not, except as required by law, reproduce or disclose to any third party any Proprietary Information or anything related to such information without the prior written consent of the Company, and shall not use any Proprietary Information except as required in the ordinary course of performing the Services.
(b) The term Proprietary Information shall mean all inventions, works of authorship, trade secrets, business plans, confidential knowledge, data or any other proprietary information of the Company. By way of illustration but not limitation, Proprietary Information includes, without limitation, (a) inventions, ideas, samples, designs, applications, sketches, drawings, methods or processes, formulas, trade secrets, data, work product, copyrights, source and object codes, gene sequences, cell lines, media, chemical compounds, assays, biological materials, models, processes, apparatuses, equipment algorithms, know-how, improvements, discoveries, developments, designs, techniques and works of authorship (hereinafter collectively referred to as Inventions); and (b) information regarding plans for research, development, engineering, experimental work, new products and service offerings, marketing and selling, business plans, budgets and unpublished financial statements, licenses, sales, pricing, profits and costs, distribution arrangements, suppliers and customers, marketing, customer and partner strategies, business development plans, customer and partner lists, information regarding the skills and compensation of employees of the Company and the Companys internal organization and the existence and terms of this Agreement. Notwithstanding the foregoing, Consultant shall not have any obligations under this Agreement with respect to a specific portion of the Proprietary Information of the Company if Consultant can demonstrate with competent evidence that such Proprietary Information:
(i) was in the public domain at the time it was disclosed or made available to Consultant by Company;
(ii) entered the public domain subsequent to the time it was disclosed or made available to Consultant by Company, through no fault, action or breach of Consultant;
(iii) was in Consultants possession free of any obligation of confidence at the time it was disclosed or made available to Consultant by Company; or
(iv) was rightfully communicated to Consultant free of any obligation of confidence subsequent to the time it was disclosed or made available to Consultant by Company.
(c) Consultant agrees to disclose to the Company in writing, and hereby assigns to the Company, Consultants entire right, title and interest in and to any and all Inventions and Proprietary Information that are made, conceived, or reduced to practice by Consultant, either alone or jointly with others, in the course of performing Services hereunder, without any obligation of the Company to pay royalty or any consideration other than as provided in this Agreement. Consultant agrees that all such Inventions and Proprietary Information are the sole property of the Company. Consultant acknowledges that all work performed by Consultant for the Company is on a work for hire basis. Consultant will, at the Companys request, promptly execute a written assignment to the Company of title of any such Inventions and Proprietary Information and will take reasonable steps to preserve any such information as part of the Proprietary Information of the Company. Consultant will cooperate fully with the Company, both during and after the term of this Agreement, with respect to the procurement, maintenance and enforcement of intellectual property rights in Inventions and Proprietary Information. The Company will compensate Consultant at a reasonable rate for the time actually spent by Consultant at the Companys request on such assistance.
2.
Confidential Information
(d) Consultant agrees that if in the course of performing the Services, Consultant incorporates into any Invention developed hereunder any invention, improvement, development, concept, discovery or other proprietary information owned by Consultant or in which Consultant has an interest (Background Technology), the Company is hereby granted and shall have a nonexclusive, royalty-free, fully paid-up, perpetual, irrevocable, sublicensable, worldwide license to make, have made, modify, use and sell, import and export such Background Technology as part of or in connection with such Invention.
(e) In the event the Company is unable, after reasonable effort, to secure Consultants signature on any document needed to apply for or prosecute or enforce or protect any patent, copyright, or other right or protection relating to a Company Invention, Consultant hereby designates and appoints the Company and its duly authorized officers and agents as Consultants agent and attorney-in-fact, to act for and on his behalf to execute, verify and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, and other rights and protections thereon with the same legal force and effect as if executed by him. Such appointment shall be irrevocable and coupled with an interest.
(f) Consultant gives Company limited permission to use his name during the Term of this Agreement solely in connection with presentations or other discussions describing the Company to third parties (e.g., regarding potential research relationships).
6. Nondisclosure of Third-Party Information. Consultant understands that the Company has received and will receive from third parties information that is confidential or proprietary and that is subject to restrictions on the Companys use and disclosure (Third-Party Information). During the term of this Agreement and after its termination, provided that Consultant is made aware of any restrictions application to any Third-Party Information, Consultant will keep such Third-Party Information confidential and will not disclose or use Third-Party Information, except as permitted by agreement between the Company and the relevant third party or as required by law, unless expressly authorized to act otherwise by an officer of the Company.
7. Obligation to Keep Company Informed. During the term of this Agreement, Consultant shall promptly disclose to the Company, or any persons designated by it, fully and in writing and will hold in trust for the sole right and benefit of the Company any and all Inventions relating to the business of the Company, whether or not patentable, of which Consultant becomes aware in the course of performing Services for the Company; provided, however, Consultant shall not be obligated to disclose information received by Consultant from others under a contractual obligation of confidentiality. Consultant agrees that Consultant will from time to time during the term of this Agreement keep the Company advised as to Consultants progress in performing the Services hereunder and that Consultant will, as requested by the Company, prepare written reports with respect thereto.
8. No Conflicting Obligation. Consultant represents that Consultants performance of this Agreement and the Services does not and will not breach or conflict with any agreement to which Consultant is or becomes a party. Consultant has not entered into, and agrees not to enter into, during the term of this Agreement, any agreement, written or oral, in conflict with this Agreement.
9. No Improper Use of Materials. Consultant agrees not to bring to the Company or to use in the performance of Services for the Company any materials, documents or information of a present or former employer of Consultant or of Consultants employees, or any materials, documents or information obtained by Consultant under an obligation of confidentiality imposed by reason of another of Consultants contractual relationships, unless such materials, documents or information are generally available to the public or Consultant has authorization from such present or former employer, client, employee or third party for the possession and unrestricted use of such materials. Consultant understands that Consultant is not to breach any obligation of confidentiality that Consultant has to present or former employers, clients or third parties, and agrees to fulfill all such obligations during the term of this Agreement.
3.
Confidential Information
10. Term and Termination. Unless previously terminated or extended, this Agreement will terminate on December 31, 2016; provided that the term of this Agreement will automatically be renewed and extended for successive six-month periods unless terminated by either party by giving the other party at least thirty (30) days prior written notice prior to the end of the then-current term (such initial or renewal term, as the case may be, the Term). Furthermore, either of the Company or Consultant may terminate this Agreement prior to the end of the Term with at thirty (30) days prior written notice to the other. The obligations set forth in paragraphs 3, 4, 5, 6, 10, 11, 13 and 14 will survive any termination of this Agreement. Upon termination of this Agreement, Consultant will promptly deliver to the Company all documents and other materials of any nature pertaining to the Services, together with all documents and other items containing or pertaining to any Proprietary Information. Consultant shall not retain copies of any such documents or other materials after termination of this Agreement.
11. Legal and Equitable Remedies. Because Consultants services are personal and unique and because Consultant may have access to and become acquainted with the Proprietary Information of the Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.
12. Assignment. The rights and liabilities of the parties hereto shall bind and inure to the benefit of their respective successors, assigns, heirs, executors and administrators, as the case may be; provided that Consultant may not assign or delegate Consultants obligations under this Agreement either in whole or in part without the prior written consent of the Company; any purported assignment without such prior written consent shall be void.
13. Governing Law; Severability. This Agreement shall be governed by the laws of the State of California as those laws are applied to contracts entered into and performed in California by California residents. Consultant hereby agrees to consent to personal jurisdiction of the state and federal courts situated within the state of California for purposes of enforcing this Agreement, and waive any objection that Consultant might have to personal jurisdiction or venue in those courts. If one or more of the provisions in this Agreement are deemed unenforceable by law, then such provision will be deemed stricken from this Agreement and the remaining provisions will continue in full force and effect. If any action or proceeding is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.
14. Complete Understanding; Modification; Waiver. This Agreement constitutes the final, exclusive and complete understanding and agreement of the parties hereto and supersedes all prior understandings and agreements. This Agreement is entered into without reliance upon any representation, whether oral or written, not stated herein. Any waiver, modification or amendment of any provision of this Agreement by a party shall be effective only if in writing and signed by an authorized representative of each party. The failure of either party to enforce at any time any of the provisions of this Agreement, or the failure to require at any time performance by the other party of any of the provisions of this Agreement, shall in no way be construed to be a present or future waiver of such provisions, nor in any way affect the right of either party to enforce each and every such provision thereafter. The express waiver by either party of any provision, condition or requirement of this Agreement shall not constitute a waiver of any future obligation to comply with such provision, condition or requirement.
4.
Confidential Information
15. Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery to the appropriate address or sent by certified or registered mail, three days after the date of mailing.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.
CIDARA THERAPEUTICS, INC. |
CONSULTANT | |||||||
By: |
/s/ Jeffrey Stein |
Signature: |
/s/ Dirk Thye | |||||
Jeffrey Stein |
Dirk Thye | |||||||
Address: |
||||||||
6310 Nancy Ridge Dr, Suite 101 |
||||||||
San Diego, CA 92121 |
5.
Confidential Information